# Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

> **NCT07637929** · — · NOT_YET_RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)

## Interventions

- **DRUG:** Puzolcabtagene Autoleucel Injection

## Key facts

- **NCT ID:** NCT07637929
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2032-12
- **Final completion:** 2032-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637929, "Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*